Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

被引：4
|
作者：
Planchard, D. [1 ]
Brahmer, J. R. [2 ]
Yang, J. C-H. [3 ]
Kim, H. R. [4 ]
Li, R. K. [5 ]
Han, J-Y. [6 ]
Cortinovis, D. L. [7 ]
Runglodvatana, Y. [8 ]
Nakajima, E. [9 ]
Ragone, A. [10 ]
Winter, M. [11 ]
Gustavson, M. [12 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] Johns Hopkins Kimmel Canc Ctr, Thorac Oncol Program, Baltimore, MD USA
[3] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan
[4] Yonsei Canc Ctr, Div Med Oncol, Dept Internal Med, Seoul, South Korea
[5] St Lukes Med Ctr Quezon City, Dept Med Oncol, Quezon City, Philippines
[6] Natl Canc Ctr, Ctr Lung Canc, Grad Sch Canc Sci & Policy, Goyang, South Korea
[7] Fondazione IRCCS San Gerardo dei Tintori, SC Oncol Med, Monza, Italy
[8] Navamindradhiraj Univ, Div Med Oncol, Vajira Hosp, Fac Med, Bangkok, Thailand
[9] AstraZeneca, Late Dev Oncol, R&D, Gaithersburg, MD USA
[10] AstraZe neca, Late Dev Oncol, R&D, Mississauga, ON, Canada
[11] AstraZeneca, Data Sci & Quantitat Biol, Cambridge, England
[12] AstraZeneca, Translat Med, Oncol R&D, Gaithersburg, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1507TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Phase Ib Study of Osimertinib and Tegavivint as First-Line Therapy in Patients with Metastatic EGFRMutant Non-Small Cell Lung Cancer (NSCLC)
    Memmott, R.
    Gheeya, J.
    Wei, L.
    Phelps, M.
    Yang, W.
    Stenehjem, D.
    Horrigan, S.
    Duncan, A.
    Uribe, D.
    Amato, G.
    Otterson, G.
    Kaufman, J.
    Alahmadi, A.
    Presley, C.
    Owen, D.
    Carbone, D.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S346 - S346
  • [22] Bevacizumab in combination with first-line metastatic chemotherapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): Results from the cohort study EOLE.
    Chouaid, Christos
    Schott, Roland
    Falchero, Lionel
    Bonnetain, Franck
    Neaume, Julien
    Bennouna, Jaafar
    Tagieva, Naila
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] First-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) in China in the era of precision medicine
    Zhang, X.
    Zhou, Q.
    Song, Y.
    Chen, G. Y.
    Zhong, D. S.
    Yu, Z.
    Yu, P.
    Zhang, Y. P.
    Chen, J. H.
    Hu, Y.
    Feng, G. S.
    Song, X.
    Shi, Q.
    Yang, L. L.
    Zhang, P. H.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02
    Janne, P.
    Goto, Y.
    Kubo, T.
    Ninomiya, K.
    Kim, S. -W.
    Planchard, D.
    Ahn, M. -J.
    Smit, E. F.
    de Langen, A. J.
    Perol, M.
    Pons-Tostivint, E.
    Novello, S.
    Hayashi, H.
    Shimizu, J.
    Kim, D. -W.
    Pereira, K.
    Cheng, F. -C.
    Taguchi, A.
    Cheng, Y.
    Goto, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S148 - S148
  • [25] AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion plus advanced/metastatic non-small cell lung cancer (NSCLC).
    Besse, Benjamin
    Felip, Enriqueta
    Clifford, Corinne
    Louie-Gao, Melinda
    Green, Jennifer
    Turner, Christopher D.
    Popat, Sanjay
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
    Cortes, J.
    Kim, S-B.
    Chung, W-P.
    Im, S-A.
    Park, Y. H.
    Hegg, R.
    Kim, M. H.
    Tseng, L-M.
    Petry, V.
    Chung, C-F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Verma, S.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1287 - S1288
  • [27] EGFR, HER2, and phospho-Akt are not predictive factors for response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
    Toschi, L.
    Metro, G.
    Magrini, E.
    Bartolini, S.
    Ligorio, C.
    Finocchiaro, G.
    Pession, A.
    Cancellieri, A.
    Tallini, G.
    Cappuzzo, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 391S - 391S
  • [28] Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
    Pelicon, Veronika
    Cufer, Tanja
    Knez, Lea
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study.
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Nishiwaki, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [30] Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC)
    Khatri, Amit
    Polhamus, Daniel
    Cobbina, Enoch
    Garcia, Ramon
    Yoder, Todd
    Abutarif, Malaz
    Garimella, Tushar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345